Lei Zheng, Xuesong Huang, Wenyi Ouyang, Gang Chen*, Annie Xiaoyu An, Jean-Pierre Wery, Jay Liu*, Xin Dong*, Qian Shi, and Davy Xuesong Ouyang
*Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing, China
Research is currently ongoing on how to improve the low overall response rate to checkpoint inhibitors, potentially through combination with other immunotherapeutics or new checkpoint targets e.g. TIM-3. TIM-3 and PD-1 co-expression is often associated with an exhausted phenotype of tumor infiltrating lymphocytes, and TIM-3 expression has been reported as a compensatory mechanism in PD-1 non-responsive patients.
Simultaneously targeting PD-1 and TIM-3 is currently being evaluated in clinical trials; however, we are lacking animal models that can efficiently evaluate the efficacy of therapeutic TIM-3 antibodies and combination regimens.
CrownBio has therefore developed a human TIM-3 knock-in mouse model, with exons 2-5 of the mouse HAVCR2 gene replaced with the human counterpart. The mouse model expresses chimeric TIM-3 on stimulated CD4 and CD8 T cells, which is recognized by human TIM-3 antibodies, allowing specific in vivo evaluation.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-28
landing_page
PDX/Databases